Analytical tools and chemometrics in drug development process: A review

Drug Development: Principles, Methodology and Emerging Challenges

Volumn , Issue , 2013, Pages 35-61

  Melucci, D ^a   Locatelli, C ^a   Locatelli, M ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892345613     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (77)

1. Newman D.J., Cragg G.M. Natural products as Sources of New Drugs over the last 25 Years. Journal of Natural Products, 2007, 70, 461-477.
2. Balunas M.J.; Kinghorn A.D. Drug discovery from medical plants. Life Science, 2005, 78, 431-441.
3. Tulp M.; Bohlin L. Unconventional natural sources for future drug discovery. Drug Discovery Today, 2004, 9, 450-458.
4. Korfmacher W.A. Principles and applications of LC-MS in new drug discovery. Drug Discovery Today, 2005, 10, 1357-1367.
5. Frank R.G. New estimates of drug development costs. Journal of Health Economics, 2003, 22, 325-330.
6. Joubert P.H. Dose optimization in drug development: role of phase 4 trials. International Congress Series, 2001, 1220, 51-65.
7. Locatelli M.; Melucci D.; Carlucci G.; Locatelli C. Recent HPLC strategies to improve sensitivity and selectivity for the analysis of complex matrices. Instrumentation Science & Technology, 2012, 40, 112-137.
8. Locatelli M. Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets. Current Drug Targets, 2011, 12, 366-380.
9. Cheng Y.F.; Lu Z.; Neuc U. Ultrafast liquid chromatography/ultraviolet and liquid chromatography/tandem mass spectrometric analysis. Rapid Communications in Mass Spectrometry, 2001, 15, 141-151.
10. Bayliss M.; Little D.; Mallett D.; Plumb R. Parallel ultra-high flow rate liquid chromatography with mass spectrometric detection using a multiplex electrospray source for direct, sensitive determination of pharmaceuticals in plasma at extremely high-throughput. Rapid Communications in Mass Spectrometry, 2000, 14, 2039-2045.
11. Zweigenbaum J.; Heinig K.; Steinborner S.; Wachs T.; Henion J. High Throughput LC/MS/MS Determination of Benzodiazepines in Human Urine-1000 sample per 12 Hours. Analytical Chemistry, 1999, 71, 2294-2300.
12. Romanyshyn L.; Tiller P. Ultra-short columns and ballistic gradients: considerations for ultra-fast chromatographic liquid chromatographic-tandem mass spectrometric analysis. Journal of Chromatography A, 2001, 928, 41-51.
13. Ayrton J.; Dear G.J.; Leavens W.J.; Mallet D.N.; Plumb R.S. The use of turbulent flow chromatography/mass spectrometry for the rapid, direct analysis of a novel pharmaceutical compound in plasma. Rapid Communications in Mass Spectrometry, 1997, 11, 1953-1958.
14. Berna M.J.; Ackermann B.L.; Murphy A.T. High-throughput chromatographic approaches to liquid chromatographic/tandem mass spectrometric bioanalysis to support drug discovery and development. Analytica Chimica Acta, 2004, 509, 1-9.
15. Efremov R.G.; Chugunov A.O.; Pyrkov T.V.; Priestle J.P.; Arseniev A.S.; Jacoby E. Molecular lipophilicity in protein modeling and drug design. Current Medicinal Chemistry, 2007, 14, 393-415.
16. Bajda M.; Boryczka S.; Malawska B. Investigation of lipophilicity of anticancer-active thioquinoline derivatives. Biomedical Chroma-tography, 2007, 21, 123-131.
17. Berthod A.; Carda-Broch S. Determination of liquid-liquid partition coefficients by separation methods. Journal of Chromatography A 2004, 1037, 3-14.
18. Ayouni L.; Cazorla G.; Chaillou D.; Herbreteau B.; Rudaz S.; Lanteri P.;Carrupt P.A. Fast determination of lipophilicity by HPLC. Chromatographia, 2005, 62, 251-255.
19. Guillaume D.; Nguyen D.T.T.; Rudaz S.; Veuthey J.L. Recent develop-ments in Liquid Chromatography: Impact on qualitative and quantitative performance. Journal of Chromatography A, 2007, 1149, 20-29.
20. Russo R.; Guillaume D.; Nguyen D.T.T.; Bicchi C.; Rudaz S.; Veuthey J.L. Pharmaceutical applications on columns packed with sub-2μm particles. Journal of Chromatographic Science, 2008, 46, 199-208.
21. Henchiz Y.; Guillarme D.; Martel S.; Rudaz S.; Veuthey J-L.; Carrupt P-A. Fast log P determination by ultra-high-pressure liquid chroma-tography coupled with UV and mass spectrometry detections. Analytical and Bioanalytical Chemistry, 2009, 394, 1919-1630.
22. Toro-Funes N.; Odriozola-Serrano I.; Bosch-Fusté J.; Latorre-Moratalla M.L.; Veciana-Nogués M.T.; Izquierdo-Pulido M.; Vidal-Carou M.C. Fast simultaneous determination of free and conjugated isoflavones in soy milk by UHPLC-UV. Food Chemistry, 2012, 135, 2832-2838.
23. Fekete S.; Rudaz S.; Fekete J.; Guillaume D. Analysis of recombinant monoclonal antibodies by RPLC: Toward a generic method development approach. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 158-168.
24. Tanaka N.; Kobayashi H.; Nakanishi K.; Minakuchi H.; Ishizuka N. Monolithic columns - a new type of chromatographic support for liquid chromatography. Analytical Chemistry, 2001, 73, 420A-429A.
25. Mazzeo J.R.; Neue U.D.; Kele M.; Plumb R.S. A new separation technique takes advantage of sub-2 μm porous particles. Analytical Chemistry, 2005, 77, 460A-465A.
26. Guiochon G. Monolithic Columns in High Performance Liquid Chromatography. Journal of Chromatography A, 2007, 1168, 101-168.
27. Unger K.K.; Skudas R.; Schulte M.M. Particle Packed Columns and Monolithic Columns in High Performance Liquid Chromatography-Comparison and Critical Appraisal. Journal of Chromatography A, 2008, 1184, 393-415.
28. Cabrera K.; Lubda D.; Eggenweiler H.; Minakuchi H.; Nakanishi K. A new monolithic-type HPLC column for fast separations. Journal of High Resolution Chromatography, 2000, 23, 93-99.
29. Dear G.; Plumb R.; Mallet D. Use of monolithic silica columns to increase analytical throughput for metabolite identification by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2001, 15, 152-158.
30. Plumb R.; Dear G.; Mallet D.; Ayrton J. Direct analysis of pharmaceutical compounds in human plasma with chromatographic resolution using an alkyl-bonded silica rod column. Rapid Communi-cations in Mass Spectrometry, 2001, 15, 986-993.
31. Locatelli M.; Governatori L.; Carlucci G.; Genovese S.; Mollica A.; Epifano F. Recent application of analytical methods to phase I and phase II drugs development: a review. Biomedical Chromatography, 2012, 26, 283-300.
32. CDER and CVM Guidance for Industry, Bioanalytical Method Validation. Food and Drug Administration, May 2001. http://www.fda.gov\cder\guidance\4252fnl.pdf.
33. http://www.camag.com/tlc-ms
34. Szymański P.; Markowicz M.; Mikiciuk-Olasik E. Adaptation of High-Throughput Screening in Drug Discovery-Toxicological Screening Tests. International Journal of Molecular Sciences, 2012, 13, 427-452.
35. Martis E.A.; Radhakrishnan R.; Badve R.R. High-throughput screening: The hits and leads of drug discovery-An overview. Journal of Applied Pharmaceutical Science, 2011, 1, 2-10.
36. Armstrong J.W. A review of high-throughput screening approaches for drug discovery. American Biotechnology Laboratory, 1999, 17, 26-28.
37. Fernandes T.G.; Diogo M.M.; Clark D.S.; Dordick J.S.; Cabral J. High-throughput cellular microarray platforms: Applications in drug discovery, toxicology and stem cell research. Trends in Biotechnology, 2009, 27, 342-349.
38. Fara D.C.; Oprea T.; Prossnitz E.R.; Bologa C.G.; Edwards B.S.; Sklar L.A. Integration of virtual and physical screening. Drug Discovery Today, 2006, 3, 337-385.
39. Hann M.; Opera T.I. Pursuing the leadlikeness concept in pharma-ceutical research. Current Opinion in Chemical Biology, 2004, 8, 255-263.
40. Clark R.L.; Johnston B.F.; Mackay S.P.; Breslin C.J.; Robertson M.; Harley A.L. The drug discovery portal: A resource to enhance drug discovery from Akademia. Drug Discovery Today, 2010, 15, 679-683.
41. Roda A.; Sabatini L.; Barbieri A.; Guardigli M.; Locatelli M.; Violante F.S.; Rovati L.C.; Persiani S.; Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. Journal of Chromatography B, 2006, 844, 119-126.
42. Pastorini E.; Locatelli M.; Simoni P.; Roda G.; Roda E.; Roda A. Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. Journal of Chromatography B, 2008, 872, 99-106.
43. Traylor M.J.; Ryan J.D.; Arnon E.S.; Dordick J.S.; Clark D.S. Rapid and quantitative measurement of metabolic stability without chromatography or mass spectrometry. Journal of the American Chemical Society, 2011, 133, 14476-14479.
44. Razgulin A.; Ma N.; Rao J. Strategies for in vivo imaging of enzyme activity: An overview and recent advances. Chemical Society Reviews, 2011, 40, 4186-4216.
45. Bialkowska A.B.; Crisp M.; Bannister T.; He Y.; Chowdhury S.; Schurer S.; Chase P.; Spicer T.; Madoux F.; Tian C.; Hodder P.; Zaharevitz D.; Yang, V.W. Identification of small-molecule inhibitors of the colorectal cancer oncogene Krüppel-like factor 5 expression by ultrahigh-throughput screening. Molecular Cancer Therapeutics, 2011, 10, 2043-2051.
46. Kasibhatla S.; Gourdeau H.; Meerovitch K.; Drewe J.; Reddy S.; Qiu L.; Zhang H.; Bergeron F.; Bouffard D.; Yang Q.; Herich J.; Lamothe S.; Cai S.X.; Tseng B. Discovery and mechanism of action of novel series of apoptosis inducers with potential vascular targeting activity. Molecular Cancer Therapeutics, 2004, 3, 1365-1373.
47. Mueller H.; Kassack M.; Wiese M. Comparison of the usefulness of MTT, ATP and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. Journal of Biomolecular Screening, 2004, 9, 506-515.
48. Koh H.L.; Yau W.P.; Ong P.S.; Hegde A. Current trends in modern pharmaceutical analysis for drug discovery. Drug Discovery Today, 2003, 8, 889-897.
49. Wierling P.S.; Bogumil R.; Knieps-Grünhagen E.; Hubbuch J. Highthroughput screening of packed-bed chromatography coupled with SELDI-TOFMS analysis: monoclonal antibodies versus host cell protein. Biotechnology and Bioengineering, 2007, 98, 440-450.
50. Dismer F.; Petzold M.; Hubbuch J. Effects of ionic strength and mobile phase pH on the binding orientation of lysozyme on different ion-exchange adsorbents. Journal of Chromatography A, 2008, 1194, 11-21.
51. Flatman S.; Alam I.; Gerard J.; Mussa N. Process analytics for purification of monoclonal antibodies. Journal of Chromatography B, 2007, 848, 79-87.
52. Rasmussen M.A.; Colding-Jørgensen, M.; Hansen, L.T.; Bro, R. Multivariate evaluation of pharmacological responses in early clinical trials - A study of rIL-21 in the treatment of patients with metastatic melanoma. British Journal of Clinical Pharmacology, 2010, 69 (4), 379-390.
53. Maltesen M.J.; Bjerregaard S.; Hovgaard L. ; Havelund S.; van de Weert M. Quality by design - Spray drying of insulin intended for inhalation. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70 (3), 828-838.
54. Farag M.A.; Wessjohann L.A. Metabolome classification of commercial hypericum perforatum (StJohn's Wort) preparations via UPLC-qTOF-MS and chemometrics. Planta Medica, 2012, 78 (5), 488-496.
55. Stanimirova I.; Michalik K.; Drzazga Z.; Trzeciak H.; Wentzell P.D.; Walczak B. Interpretation of analysis of variance models using principal component analysis to assess the effect of a maternal anticancer treatment on the mineralization of rat bones. Analytica Chimica Acta, 2011, 689 (1), 1-7.
56. Rocha J.R.; Freitas R.F.; Montanari C.A. The GRID/CPCA approach in drug discovery. Expert Opinion on Drug Discovery, 2010, 5 (4), 333-346.
57. Fan G.; Deng R.; Zhou L.; Meng X.; Kuang T.; Lai X.; Zhang J.; Zhang Y. Development of a rapid resolution liquid chromatographic method combined with chemometrics for quality control of Angelicae dahuricae radix. Phytochemical Analysis, 2012, 23 (4), 299-307.
58. Rajalahti T.; Kvalheim O.M. Multivariate data analysis in pharmaceutics: A tutorial review. International Journal of Pharmaceutics. 2011, 417 (1-2), 280-290.
59. Cui Y.; Song X.; Chuang K.; Venkatramani C.; Lee S.; Gallegos G.; Venkateshwaran,T.; Xie, M. Variable selection in multivariate modeling of drug product formula and manufacturing process. Journal of Pharmaceutical Sciences, 2012, in press.
60. Ni Y.; Liu Y.; Kokot S. Two-dimensional fingerprinting approach for comparison of complex substances analysed by HPLC-UV and fluorescence detection. Analyst, 2011, 136 (3), 550-559.
61. Ajayakumar P.V.; Chanda D.; Pal A.; Singh M.P.; Samad A. FT-NIR spectroscopy for rapid and simple determination of nimesulide in rabbit plasma for pharmacokinetic analysis. Journal of Pharmaceutical and Biomedical Analysis, 2012, 58 (1), 157-162.
62. Melucci D.; Monti D.; D'Elia M.; Luciano G. Rapid in-situ repeatable analysis of drugs in powder form using reflectance Near-Infrared Spectroscopy and multivariate calibration. Journal of Forensic Sciences, 2012, 57, 86-92.
63. Wang X.; Sun H.; Zhang A.; Wang P.; Han Y. Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. Journal of Separation Science, 2011, 34 (24), 3451-3459.
64. Andersson M.; Ringberg A.; Gustafsson C. Multivariate methods in tablet formulation suitable for early drug development: Predictive models from a screening design of several linked responses. Chemometrics and Intelligent Laboratory Systems, 2007, 87 (1), 151-156.
65. So Y.U.; Myeon W.C.; Kim K.-B.; Seon H.K.; Ji,S.O.; Hye Y.O.; Hwa J.L.; Ki H.C. Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats. Analytical Chemistry, 2009, 81 (12), 4734-4741.
66. Hao M.; Li Y.; Wang Y.; Zhang S. A classification study of respiratory syncytial virus (RSV) inhibitors by variable selection with random forest. International Journal of Molecular Sciences, 2011, 12 (2), 1259-1280.
67. Van de Waterbeemd H.; Gifford E. ADMET in silico modelling: Towards prediction paradise? Nature Reviews Drug Discovery, 2003, 2 (3), 192-204.
68. Wolohan P.R.N.; Clark R.D. Predicting drug pharmacokinetic properties using molecular interaction fields and SIMCA. Journal of Computer-Aided Molecular Design, 2003, 17 (1), 65-76.
69. Rosas J.G.; Blanco M.; González J.M.; Alcalá M. Quality by design approach of a pharmaceutical gel manufacturing process, part 1: Determination of the design space. Journal of Pharmaceutical Sciences, 2011, 100 (10), 4432-4441.
70. Korakianiti E.; Rekkas D. Statistical thinking and knowledge management for quality-driven design and manufacturing in pharmaceuticals. Pharmaceutical Research, 2011), 28 (7), 1465-1479.
71. Wilcoxen K.M.; Uehara T.; Myint K.T.; Sato Y.; Oda Y. Practical metabolomics in drug discovery. Expert Opinion on Drug Discovery, 2010, 5 (3), 249-263.
72. Kadam S.S.; Vissers J.A.W.; Forgione M.; Geertman R.M.; Daudey P.J.; Stankiewicz A.I.; Kramer H.J.M. Rapid crystallization process development strategy from lab to industrial scale with PAT tools in skid configuration. Organic Process Research and Development, 2012), 16 (5), 769-780.
73. Talevi A.; Bellera C.L.; Di Ianni M.; Duchowicz P.R.; Bruno-Blanch L.E.; Castro E.A. An Integrated drug development approach applying topological descriptors. Current Computer-Aided Drug Design, 2012, 8 (3), 172-181.
74. Glávez J.; Glávez-Llompart M.; García-Domenech R. Molecular topology as a novel approach for drug discovery. Expert Opinion on Drug Discovery, 2012, 7 (2), 133-153.
75. Kirchmair J.; Distinto S.; Liedl K.R.; Markt P.; Rollinger J.M.; Schuster D.; Spitzer G.M.; Wolber G. Development of anti-viral agents using molecular modeling and virtual screening techniques. Infectious Disorders - Drug Targets, 2011, 11 (1), 64-93.
76. Funatsu K.; Miyao T.; Arakawa M. Systematic generation of chemical structures for rational drug design based on QSAR models. Current Computer-Aided Drug Design, 2011, 7 (1), 1-9.
77. Linusson A.; Elofsson M.; Andersson I.E.; Dahlgren M.K. Statistical molecular design of balanced compound libraries for QSAR modeling. Current Medicinal Chemistry, 2010, 17 (19), 2001-2016.